Standardy leczenia zaburzeń odżywiania

• Authors: Jolanta Rabe-Jabłońska , Tomasz Pawełczyk , Cezary Żechowski , Marek Jarema

Title variants

EN

Therapeutic standards In eating disorders

• Languages of publication: PL

Abstracts

EN

Standardy leczenia zaburzeń odżywiania są kolejnymi po standardach leczenia schizofrenii i chorób afektywnych standardami przygotowanymi dla psychiatrów polskich. Opracowano je z inicjatywy specjalisty krajowego do spraw psychiatrii - prof. Marka Jaremy, na podstawie najnowszej wiedzy, przeglądu innych standardów wydanych do tej pory na świecie, a także doświadczeń własnych ośrodków zajmujących się tą problematyką. Zostały one opublikowane w „Farmakoterapii w Psychiatrii i Neurologii" w 2007 roku (t. 23, wrzesień, zeszyt 3). Ze względu jednak na fakt, że do tej pory nie istniały polskie standardy postępowania w przypadku zaburzeń odżywiania, i na potrzebę jak najszerszego ich rozpropagowania postanowiliśmy je wydrukować również w „Psychiatrii i Psychologii Klinicznej".

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Psychiatria i Psychologia Kliniczna
• Year: 2008
• Volume: 8
• Issue: 1
• Pages: 20-40

Contributors

author

Jolanta Rabe-Jabłońska

• Klinika Zaburzeń Afektywnych i Psychotycznych, Katedra Psychiatrii Uniwersytetu Medycznego w Łodzi. Kierownik: prof. dr hab. n. med. Jolanta Rabe-Jabłońska

author

Tomasz Pawełczyk

• Klinika Zaburzeń Afektywnych i Psychotycznych, Katedra Psychiatrii Uniwersytetu Medycznego w Łodzi. Kierownik: prof. dr hab. n. med. Jolanta Rabe-Jabłońska

author

Cezary Żechowski

• Klinika Psychiatrii Dzieci i Młodzieży, Instytut Psychiatrii i Neurologii. Kierownik: prof. dr hab. n. med. Irena Namysłowska

author

Marek Jarema

• III Klinika Psychiatryczna, Instytut Psychiatrii i Neurologii. Kierownik: prof. dr hab. n. med. Marek Jarema

References

• 1. Advokat C., Kutlesic V: Pharmacotherapy of the eating disorders: a commentary. Neurosci. Biobehav. Rev. 1995: 19: 59-66.
• 2. Agras WS.: Treatment of binge eating disorder. W: Gab-bard G.O. (red.): Treatments of Psychiatric Disorders. Wyd. 3, American Psychiatric Press, Washington, DC 2001: 2209-2219.
• 3. Agras WS., Telch D.F., Arnow B.: Weight loss, cognitive - behavioral, and desipramine treatments in binge eating disorder. An additive design. Behav. Ther. 1004; 25: 225-238.
• 4. Allende L.M., Corell A., Manzanares J. i wsp.: Immunodeficiency associated with anorexia nervosa is secondary and improves after refeeding. Immunology 1998; 94: 543-551.
• 5. Alvin P., Zogheib J.: Severe complications and mortality in mental eating disorders in adolescence. On 99 hospitalized patients. Arch. Fr. Pediatr. 1993; 50: 755-762.
• 6. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Wyd. 4, APA, Washington, DC 1994.
• 7. Anderson J.W., Greenway F.L., Fujioka K.: Bupropion SR enhances weight loss: a 48 - week double-blind, placebo-controlled trial. Obes. Res. 2002; 10: 633-641.
• 8. Appolinario J.C., Bacaltchuk J., Sichieri R.: Arandomized double-blind, placebo-controlled study of sibutramine in the treatment of binge eating disorder. Arch. Gen. Psychiatry 2003; 60: 1109-1116.
• 9. Appolinario J.C., Mcelroy S.L.: Pharmacological approaches in the treatment of binge eating disorder. Curr. Drug. Targets 2004; 5: 301-307.
• 10. Arnold L.M., mcElroy S.L., Hudson J.I. i wsp.: A placebo-controlled, randomized trial of fluoxetine in the treatment of binge - eating disorder. J. Clin. Psychiatry 2002; 63: 1028-1033.
• 11. Audi L., Vargas D.M., Gussinye M. i wsp.: Clinical and biochemical determinants of bone metabolism and bone mass in adolescent female patients with anorexia nervosa. Pediatr. Res. 2002; 51: 1-8.
• 12. Backett S.A.: Acute pancreatitis and gastric dilatation in a patient with anorexia nervosa. Postgrad. Med. J. 1985; 61: 39-40.
• 13. Ballauff A., Ziegler A., Emons G.: Serum leptin and gonadotropin levels in patients with anorexia nervosa during weight gain. Mol. Psychiatry 1999; 4: 71-75.
• 14. Bessler H., Karp I., Notti L. i wsp.: Cytokine production in anorexia nervosa. Clin. Neuropharmacol. 1993; 1: 237-243.
• 15. Biederman J., Herzog D.B., Rivinus T.M. i wsp.: Amit-ryptyline in the treatment of anorexia nervosa: a doubleblind placebo-controlled study. J. Clin. Psychopharmacol. 1985; 5: 10-16.
• 16. Bonne O.B., Bloch M., Berry E.M.: Adaptation to severs chronic hipokaliemia in anorexia nervosa: a plea for conservative management. Int. J. Eat. Disord. 1993; 13: 125-128.
• 17. Brabiuche M.R., Levy-Soussan P.: Anorexia nervosa and lower vulnerability to infections. Am. J. Psychiatry 1993; 150: 169-170.
• 18. Brambilla F., Draisci A., Peirone A., Brunetta M.: Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 2. Anorexia nervosa - binge-eating/purging type. Neuropsychobiology 1995; 32: 64-67.
• 19. Brambilla F., Ferrari E., Brunetta M. i wsp.: Immunoendocrine aspects of anorexia nervosa. Psychiatry Res. 1996; 16: 97-104.
• 20. Branson R., Potoczna N., Kral J.G.: Binge eating as a major phenotype of melanocortin 4 receptor gene mutations. N. Engl. J. Med. 2003; 348: 1096-1103.
• 21. Braun D.L., Sunday S.R., Halmi K.A.: Psychiatric comorbidity in patients with eating disorders. Psychol. Med. 1994; 24: 859.
• 22. Bray G.A., Hollander P., Klein S.: A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res. 2003; 11: 722-733.
• 23. Carter WP., Hudson J.I., Lalonde J.K. i wsp.: Pharmacological treatment of binge eating disorder. Int. Eat. Disord. 2003; 34 supl.: S74-S88.
• 24. Casper R.C.: Personality features of women with good outcome from restricting anorexia nervosa. Psychosom. Med. 1990; 52: 156.
• 25. Cooke R.A., Chambers J.B.: Anorexia nervosa and the heart. Br. J. Hosp. Med. 1995; 54: 313-317.
• 26. Cooke R.A., Chambers J.B., Singh R. i wsp.: QT interval in anorexia nervosa. Br. Heart J. 1994; 72: 69-73.
• 27. Crisp A.H., Callender J.S., Halek C. i wsp.: Long-term mortality in anorexia nervosa. A 20 year follow-up of the St. George's and Aberdeen cohorts. Br. J. Psychiatry 1992; 161: 104-107.
• 28. Crisp A.H., Palmer R.L., Kaluchy R.S.: How common is anorexia nervosa? A prevalent study. Br. J. Psychiatry 1976; 128: 549.
• 29. Devlin M.J., Goldfein J.A., Petkova E. i wsp.: Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder. Obes. Res. 2005; 13: 1077-1088.
• 30. De Zwaan M.: Binge eating disorder and obesity. Int. J. Obes. Relat. Metab. Disord 2001; 25 (supl. 1): 51-55.
• 31. Durakovic Z., Durakovic A., Korsic M.: Changes of the corrected QT interval in the electrocardiogram of patients with anorexia nervosa. Int. J. Cardiol. 1994; 45: 115-120.
• 32. Eckert E.D., Halmi K.A., Marchi E.P: Ten-year follow-up of anorexia nervosa: clinical course and outcome. Psychol. Med. 1995; 25: 143.
• 33. Fairburn C.G. i wsp.: Cognitive-behavioural therapy for binge eating and bulimia nervosa; a comprehensive treatment manual. W: Fairburn C.G., Wilson G.T. (red.): Binge Eating: Nature, Assessment and Treatment. Guilford Press, New York 1993: 361-404.
• 34. Frank G.K., Kaye WH., Marcus M.D.: Sertraline in underweight binge eating/purging - type eating disorders: five case reports. Int. J. Eat. Disord. 2001; 29: 495-498.
• 35. Gniuli D., Liverani E., Capristo E. i wsp.: Blunted glucose metabolism in anorexia nervosa. Metabolism 2001; 50: 876-881.
• 36. Goldstein D.J., Wilson M.G., Ascroft R.C., al-Banna W: Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression. Int. J. Eat. Disord. 1999; 25: 19-27.
• 37. Gorwood P.: Eating disorders, serotonin transporter polymorphisms and potential treatment response. Am. J. Pharmacogenomics 2004; 4: 9-17.
• 38. Grilo C.M.: A controlled study of cognitive behavioral therapy and fluoxetine in binge eating disorder. Charleston S.C.: Eating Disorders Research Society, Annual Meeting of APA2002.
• 39. Halmi K.A., Eckert E., Marchi E.P. i wsp.: Comorbidity of psychiatric diagnosis in anorexia nervosa. Arch. Gen. Psychiatry 1991; 48: 712.
• 40. Hay P.J., Bacaltchuck J.: Psychotherapy for bulimia nervosa and binging. Cochrane Database Syst. Rev. 2000; (4): CD000562.
• 41. Hoopes S.P., Reimherr F.W., Hedges D.W. i wsp.: Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J. Clin. Psychiatry 2003; 64: 1335-1341.
• 42. Hudson J.I., Carter W.P., Pope H.G. Jr: Antidepressants treatment of binge - eating disorder: research findings and clinical guidelines. J. Clin. Psychiatry 1996; 57 supl.: 73-79.
• 43. Hudson J.I., McElroy S.L., Raymond N.C. i wsp.: Fluvoxamine in the treatment of binge - eating disorder: a multicenter placebo-controlled, double-blind study. Am. J. Psychiatry 1998; 155: 1756-1762.
• 44. Jagielska G., Wolańczyk T., Komender J. i wsp.: Bone mineral content and bone mineral density in adolescents girls with anorexia nervosa: a longitudinal study. Acta Psychiatr. Scand. 2001; 104: 131-137.
• 45. Jagielska G., Tomaszewicz-Libudzic C., Brzozowska A., Komender J.: Zaburzenia kardiologiczne u chorych na jadłowstręt psychiczny. Psychiatr. Pol. 2001; 35: 81-91.
• 46. Jimerson D.C., Herzog D.B., Brotman A.W.: Pharmacologic approaches in the treatment of eating disorders. Harv. Rev. Psychiatry1993; 1: 82-93.
• 47. Kaplan A.S.: Academy for Eating Disorder International Conference on Eating Disorders. Denver, CO, USA, May 29-31,2003. Expert Opin. Investig. Drugs 2003; 12: 1441-1443.
• 48. Keel PK., Mitchell J., Miller K. i wsp.: Long term outcome of bulimia nervosa. Arch. Gen. Psychiatry 1999; 55: 63.
• 49. Keel P., Dorer D.J., Eddy K.T. i wsp.: Predictors of mortality in eating disorders. Arch. Gen. Psychiatry2003; 60: 179-183.
• 50. KollaiM., BonyhayI., Jokkel G., SzonyiL.: Cardiac vagal hyperactivity in adolescent anorexia nervosa. Eur. Heart J. 1994; 15: 1113-1118.
• 51. Komender J., Popielarska A., Tomaszewicz-Libudzic E. i wsp.: Odlegle wyniki leczenia dorastających chorych na jadłowstręt psychiczny. Psychiatr. Pol. 1998; 32: 759-769.
• 52. Komorowska-Pietrzykowska R., Rajewski A., Sobieska M., Wiktorowicz K.: Interleukin 6, tumor necrosis factor a and interferon y in patients with anorexia nervosa. Progres in Basic and Clinical Immunology, Kluwer Academic/Plenum Publishers, New York 2001.
• 53. Korndörfer S.R., Alexander R.L., Sumon V.J. i wsp.: Long-term survival of patients with anorexia nervosa: a population based study in Rochester. Minn. Mayo Clin. Proc. 2003; 78: 278-284.
• 54. Kruger S., Kennedy S.H.: Psychopharmacotherapy of anorexia nervosa, bulimia nervosa and binge-eating disorder. J. Psychiatry Neurosci. 2000; 25: 497-508.
• 55. Malhotra S., King K.H., Welge J.A. i wsp.: Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients. J. Clin. Psychiatry 2001; 63: 802-806.
• 56. Malhotra S., King K.H., Welge J.A.: Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients. J. Clin. Psychiatry 2002; 63: 802-806.
• 57. Mayer L.E., Walsh B.T.: The use of selective serotonin reuptake inhibitors in eating disorders. J. Clin. Psychiatry 1998; 59 supl.: 28-34.
• 58. McElroy S.L., Arnold L.M., Shapira N.A.: Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo controlled trial. Am. J. Psychiatry 2003; 160: 255-261.
• 59. McElroy S.L., Shapira N.A., Arnold L.M. i wsp.: Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J. Clin. Psychiatry2004; 65: 1463-1469.
• 60. McElroy S.L., Hudson J.I., Malhorta S. i wsp.: Citalo-pram in the treatment of binge eating disorder: a placebo controlled trial. J. Clin. Psychiatry2003; 64: 807-813.
• 61. McElroy S.L., Kotwal R., Hudson J.I.: Zonisamide in the treatment of binge eating disorder; an open-label, prospective trial. J. Clin. Psychiatry2004; 65: 50-56.
• 62. Meyers D.G., Starke H., Pearson P.H. i wsp.: Leaflet to left ventricular size disproportion and prolapse of a strucrurally normal mitral valve in anorexia nervosa. Am. J. Cardiol. 1987; 60: 911-914.
• 63. Milano W., Petrella C., Casella A. i wsp.: Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge-eating disorder: a placebo-controlled study. Adv. Ther. 2005; 22: 25-31.
• 64. Milner E.A., Cioffi WG., McManus W.F., Pruitt BA. Jr: Superior mesenteric artery syndrome in a burn patients. Nutr. Clin. Pract. 1995; 8: 264-266.
• 65. Mitchell J.E., Groat R.: A placebo-controlled, doubleblind trial of amitryptyline in bulimia. J. Clin. Psychopharmacol. 1984; 4: 186-193.
• 66. Mitchell J.E., de Zwaan M., Roerig J.L.: Drug therapy for patients with eating disorders. Curr. Drug. Targets CNS Neurol. Disord. 2003; 2: 17-29.
• 67. Mitchell J.E., Tareen B., Sheehan W. i wsp.: Establishing guidelines for pharmacotherapy trials in bulimia nervosa and anorexia nervosa. Int. Eat. Disord. 2000; 28: 1-7.
• 68. Mitchell J.E., Gosnell B.A., Roerig J.L.: Effects of sibutramine on binge eating, hunger, and fullness in a laboratory human feeding paradigm. Obes. Res. 2003; 11: 599-602.
• 69. Möller-Madsen S., Nystrup J., Nielsen S.: Mortality in anorexia nervosa in Denmark during the period 1970-1987. Acta Psychiatr. Scand. 1996; 94: 454-459.
• 70. National Institute for Clinical Excellence. Clinical Guideline 9. Eating disorders. Core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. National Collaborating Centre for Mental Health, January 2004.
• 71. Ogston D., Ogston WD.: The fibrinolytic enzyme system in anorexia nervosa. Acta Haematol. 1976; 55: 230-233.
• 72. Oka Y., Ito T., Matsumoto S. i wsp.: Mitral valve prolapse in patients with anorexia nervosa. Two-dimensional echocardiographic study. Jpn. Heart J. 1987; 28: 873-882.
• 73. Palmer R.L.: Death in anorexia nervosa. Lancet 2003; 361: 1490.
• 74. Patton G.C.: Mortality in eating disorders. Psychol. Med. 1988; 18: 947-951.
• 75. Pederson K.J., Roerig J.L., Mitchell J.E.: Towards the pharmacotherapy of eating disorders. Expert Opin. Pharmacother. 2003; 4: 1659-1678.
• 76. Perkins S.J., Murphy R., Schmidt U., Williams C.: Self-help and guided self-help for eating disorders. Cochrane Database Syst. Rev. 2006; 3: CD004191.
• 77. Peterson C.B., Mitchell J.E.: Psychosocial and pharmacological treatment of eating disorders: a review of research findings. J. Clin. Psychol. 1999; 55: 685-697.
• 78. Petretta M., Bonaduce D., Scalfi L. i wsp.: Heart rate variability as a measure of autonomic nervous system function in anorexia nervosa. Clin. Cardiol. 1997; 20: 219-224.
• 79. Pompili R., Mancinelli J., Ginardi P. i wsp.: Suicide in anorexia nervosa: a metaanalysis. Int. Eat. Dis. 2004; 36: 99-103.
• 80. Pope H.G. Jr, Hudson J.I., Jonas J.M., Yurgelun-Todd D.: Bulimia treated with imipramine; a placebo-controlled, double-blind study. Am. J. Psychiatry 1983; 140: 554-558.
• 81. Pope H.G. Jr, Hudson J.I., Jonas J.M., Yurgelun-Todd D.: Antidepressant treatment of bulimia: a two-year follow-up study. J. Clin. Psychopharmacol. 1985; 5: 320-327.
• 82. Pope H.G. Jr, Hudson J.I.: Treatment of bulimia with antidepressants. Psychopharmacology 1982; 78: 176-179.
• 83. Rabe-Jabłońska J. (red.): Powikłania somatyczne jadłowstrętu psychicznego. Biblioteka Psychiatrii Polskiej 2006.
• 84. Ramsay R., Ward A., Treasure J. i wsp.: Compulsory treatment in anorexia nervosa: short-term benefits and long-term mortality. Br. J. Psychiatr. 1999; 175: 147-153.
• 85. Ratnasuriya R.H., Eisler J., Szmukler G.J. i wsp.: Anorexia nervosa: outcome and prognostic factors after 20 years. Br. J. Psychiatry 1991; 158: 495-502.
• 86. Ricca V., Mannucci E., Mezzani B. i wsp.: Fluoxetine and fluvoxamine combined with individual cognitive-behaviour therapy in binge-eating disorders: a one-year follow-up study. Psychother. Psychosom. 2001; 70: 298-306.
• 87. Russell G.F.M., Shmuckler G.I., Dare C.: An evaluation of family therapy in anorexia nervosa and bulimia nervosa. Arch. Gen. Psychiatry. 2987; 44: 1047.
• 88. Sakka S., Hurst P., Khawaja H.: Anorexia nervosa and necrotizing colitis: case report and review of the literature. Postgrad. Med. J. 1994; 70: 369-370.
• 89. Schmidt U., Tiller J., Hoades M., Treasure J.: Risk factors for developmental of early onset bulimia nervosa. W: Steinhausen H.C. (red.): Eating Disorders in Adolescence. Walter de Gruyter, Berlin - New York 1995: 83-94.
• 90. Steinhausen H.C.: Clinical guidelines for anorexia nervosa and bulimia nervosa. Eur. Child Adolesc. Psychiatry 1997;6:121-128.
• 91. Steinhausen H.C., Boydjieva S., Grigoroiu-Serbanescu M. i wsp.: A transcultural outcome study of adolescent eating disorders. Acta Psychiatr. Scand. 2000; 101: 60-66.
• 92. Striegel-Moore R.H., Franco D.L.: Epidemiology of binge eating disorder. Int. J. Eat. Disord. 2003; 34 supl.: 19-29.
• 93. Sullivan P.F.: Mortality in anorexia nervosa. Am. J. Psychiatr. 1995; 152: 1073-1074.
• 94. Szmukler G.I., Young G.P, Lichtenstein M., Andrews J.T.: Aserial study of gastric emptying in anorexia nervosa and bulimia. Aust. N. Z. J. Med. 1990; 20: 220-225.
• 95. Śmiech A., Wyszogrodzka-Kucharska A., Rabe-Jabłońska J.: Układ kostny w zaburzeniach odżywiania. Postępy Psychiatr. Neurol. 2003; 12: 79-88.
• 96. Telch C.F., Agras WS., Linehan M.M.: Dialectical behavior therapy for binge eating disorder. J. Consult. Clin. Psychol. 2001; 69: 1061-1065.
• 97. Theander S.: Outcome and prognosis in anorexia nervosa and bulimia: some results of previous investigations, compared with those of a Swedish long-term study. J. Psychiatr. Res. 1985; 19: 493-508.
• 98. Thiel A.: Are psychotropic drugs necessary for the treatment of anorexia and bulimia nervosa? Psychother. Psychosom. Med. Psychol. 1997; 47: 332-345.
• 99. Tomaszewicz-Libudzic C., Jagielska G., Komender J. i wsp.: Zagrażające życiu zaburzenia metaboliczne i patofizjologiczne u chorych na jadłowstręt psychiczny. Psychiatr. Pol. 1997; 31: 713-721.
• 100. Walsh B.T, Devlin M.J.: Pharmacotherapy of bulimia nervosa and binge eating disorder. Addict. Behav. 1995; 20: 757-764.
• 101. Wilson G.T., Fairburn C.G.: Cognitive treatments for eating disorders. J. Consult. Clin. Psychol. 1993; 61: 261-269.
• 102. Yager J., Devlin M.J., Halmi K.A. i wsp.: Guideline Watch: Practice Guidelines for the Treatment of Patients with Eating Disorders. Wyd. 2, February 2005, APA.
• 103. Yaryura-Tobias J.A., Pinto A., Neziroglu F.: Anorexia nervosa, diabetes mellitus, brain atrophy, and fatty liver. Int. J. Eat. Disord. 2001; 30: 350-353.
• 104. Zhu A.J., Walsh B.T.: Pharmacologic treatment of eating disorders. Can. J. Psychiatry 2002; 47: 227-234.

• Document Type: minireview